Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

被引：38
|
作者：
Garcia, Jacqueline S.
Wei, Andrew H.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nolte, Florian
Jurcic, Joseph G.
Jacoby, Meagan A.
Hong, Wan-Jen
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Tong, Bo
Hogdal, Leah
Kamalakar, Rajesh
Hutti, Jessica E.
Kye, Steve
Garcia-Manero, Guillermo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139492
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [22] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Ganetsky, Rebecca
    Latham, Deborah
    Paulic, Katarina
    Afable, Manuel
    Saba, Hussain I.
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
  • [23] A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
    Miao, Miao
    Wu, Depei
    Xie, Shuangfeng
    Hong, Mei
    Chang, ChunKang
    Yu, Li
    Gao, Sujun
    Li, Yan
    Li, Yuhua
    Zhu, Zunmin
    Tang, Baolin
    Li, Bingzong
    Yang, Haiping
    Wang, Jishi
    Qin, Ling
    Fu, Rong
    Li, Fei
    Ma, Liangming
    Liu, Qifa
    Du, Xin
    Jiang, Zhongxing
    Li, Zhenyu
    Liu, Aijun
    Tong, Hongyan
    Ma, Jun
    Liu, Li
    Liu, Qingchi
    Xu, Yajing
    Zhou, Hui
    Wang, Yan
    Chen, Jianlin
    Niu, Ziru
    Chen, Mingxia
    Xiao, Zhijian
    BLOOD, 2022, 140 : 4045 - 4046
  • [24] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [25] WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Falconi, Giulia
    Fabiani, Emiliano
    Ottone, Tiziana
    Piciocchi, Alfonso
    Lavorgna, Serena
    Criscuolo, Marianna
    Fianchi, Luana
    Gurnari, Carmelo
    Postorino, Massimiliano
    Picardi, Alessandra
    Palmieri, Raffaele
    Lo-Coco, Francesco
    Voso, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 979 - 982
  • [26] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [28] Effectiveness of Azacitidine in Frontline Higher-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study of 382 Patients
    Nishathan, Rajakumaraswamy
    Mitul, Gandhi
    Andrew, H. Wei
    David, A. Sallman
    Navel, G. Daver
    Shuyuan, Mo
    Shahed, Iqbal
    Manli, Chen
    Yunfei, Wang
    Paresh, Vyas
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S15 - S15
  • [29] Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naive Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Jacoby, Meagan A.
    Fong, Chun Yew
    Borate, Uma
    Baer, Maria R.
    Cunningham, Ilona
    Odenike, Olatoyosi
    Jurcic, Joseph G.
    Nowak, Daniel
    Peterlin, Pierre
    Platzbecker, Uwe
    Dunshee, Diana
    Zhou, Ying
    Hoffman, David
    Sun, Yan
    Popovic, Relja
    Ainsworth, Barrett
    Naqvi, Kiran
    Kye, Steve
    Hogdal, Leah
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [30] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
    Chen, James Yuhtyng
    Johnson, Lisa
    McKenna, Kelly Marie
    Choi, Timothy S.
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan M.
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris H. M.
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345